Targovax.com is the digital front for Circio Holding ASA, a company that just pulled a high-stakes pivot. They abandoned their original cancer immunotherapy focus to chase the holy grail of biotech: circular RNA (circRNA). This isn't just a website; it's the landing page for a $8.5M bet on a new genetic architecture.

"They aren't chasing user traffic; they are chasing patent filings and clinical data."

The domain structure reveals a split focus. While the primary domain (targovax.com) currently redirects or acts as a holding page, the operational meat is at circio.com. This dual-domain strategy is messy for SEO but common in biotech mergers where legacy equity holders still need access to old info. The lack of organic traffic data isn't a failure; it's a signal that their audience is institutional investors and pharmaceutical partners, not the general public.

• CircRNA Stability: Unlike mRNA, circular RNA is resistant to degradation, offering longer protein expression.
• Targeted Delivery: Their technology focuses on delivering these circular molecules specifically to tumor cells.
• The Rebrand: The planned ticker change to 'CRNA' signals a complete shedding of the Targovax skin.